AstraZeneca agreed to license exclusive global rights to Dizal Pharmaceutical’s oral EGFR inhibitor Zegfrovy (sunvozertinib), a deal potentially worth up to $1.5 billion. The transaction follows positive Phase III WU-KONG28 data in first-line EGFR exon 20 insertion NSCLC, published in The New England Journal of Medicine, with sunvozertinib improving progression-free survival and response measures versus platinum-based chemotherapy.